The 19 kDa carboxy-terminal domain of Plasmodium yoelii merozoite surface protein-I (MSPI,,) was expressed in Salmonella vaccine strains as a carboxyterminal fusion to fragment C of tetanus toxin (TetC). This study demonstrates that antibodies that recognize disulphide-dependent conformational epitopes in native MSPI react with the TetC-MSPI,, fusion protein expressed in Salmonella. The proper folding of MSPI,, polypeptide is dependent on both the Salmonella host strain and the protein to which the MSPI,, polypeptide is fused. Serum from mice immunized with Salmonella fyphimurium C5aroD expressing TetC-MSPI ,, recognized native MSPI as shown by immunofluorescence with P. yoelii-infected erythrocytes. Antibody levels to MSPI,, were highest in out-bred mice immunized with S-typhimurium C5aroD carrying pTECH2-MSPI 19 and antibody was mostly directed against reductionsensitive conformational epitopes. However, antibody levels were lower than in BALBlc mice immunized with a glutathione S-transferase (GST)-MSPI ,, fusion protein in Freund's adjuvant, and which were protected against P. yoelii challenge infection. In challenge experiments with P. yoelii the Salmonellaimmunized mice were not protected, probably reflecting the magnitude of the antibody response. The results of this study have important implications in the design of live multivalent bacterial vaccines against eukaryotic pathogens.
INTRODUCTION
The development of multivalent vaccines for human and veterinary use, based on the expression of heterologous antigens in live attenuated Salmonella, has received considerable attention in the last decade Hormaeche & Khan, 1996; impact on morbidity and mortality in malaria-endemic areas. Surface proteins of merozoites, the form of the parasite that invades red blood cells, are important vaccine candidates. Merozoite surface protein-1 (MSPl), a protein found in all Plasmodium species, has been extensively studied as a target of protective immunity. It has been used to vaccinate in animal models against parasite challenge, including that of Plasmodium falciparum, the major human malaria (Etlinger et al., 1991; Siddiqui et al., 1987) .
The 19 kDa carboxy-terminal domain of MSPl (MSPl,,) is of particular interest as a vaccine candidate. Studies with the human malaria P. falciparum in vitro (Blackman et al., 1990; Cooper et al., 1992; Pirson & Perkins, 1985) and the rodent malaria Plasmodium yoelii in viuo (Majarian et al., 1984; Spencer Valero et al., 1998) have shown that monoclonal antibodies to reduction-sensitive epitopes in this domain are effective at inhibiting invasion of erythrocytes. The cysteine-rich sequence of MSPl,, contains at least five highly conserved disulphide bonds which generate a folded structure composed of two epidermal growth factor (EGF)-like modules (Blackman et al., 1991) . MSPl,, has been expressed in Escherichia coli in the correctly folded state as judged by antibody binding (Burghaus & Holder, 1994; Chappel & Holder, 1993) . Mice immunized with the E. coli-derived recombinant P. yoelii protein were protected against challenge infection (Daly & Long, 1993 ; Ling et al., 1994) , but the protection was abolished if the protein structure was destroyed by reduction and alkylation prior to use for immunization. This demonstrated that a recombinant MSPl,, suitable for vaccine trials has to be correctly folded (Ling et al., 1994) . More recently, it has also been shown that both EGF-like motifs present in MSPl,, are required for the induction of protective immunity (Ling et al., 1995) . Protection is predominantly mediated by antibodies (Daly & Long, 1995) .
We have previously described a system using the plasmid pTECH2 for the expression of guest antigens in Salmonella as C-terminal fusions to tetanus toxin fragment C (TetC) under the control of the anaerobically inducible promoter nirB (Chabalgoity et al., 1996; Khan et al., 1994a, b) . However, the expression of a recombinant eukaryotic protein, in which formation of disulphide bridges produces a properly folded antigenic and immunogenic molecule, has not been demonstrated previously in Salmonella.
In the present study we have used pTECH2 to express MSPl,, from P. yoelii, in a panel of different, live, attenuated Salmonella vaccine strains. We have evaluated the antigenicity and the immunogenicity of this recombinant protein and describe the delivery of MSPl,, to the mouse immune system by a live Aro Salmonella vaccine strain.
METHODS
Plasmids, oligonucleotides and bacterial strains. Plasmid pTECH2 has been described (Khan et al., 1994a) . The DNA sequence of the MSPl,, EGF-like modules, corresponding to amino acids 1649-1754 in the P. yoelii YM MSPl sequence (Lewis, 1989) , was amplified by PCR from the E. coli expression vector pGEX-3X containing the P. yoelii sequence (Ling et al., 1994) . Oligonucleotide primers containing sites for BamHI and SpeI cohesive ends (forward primer, 5' TAGG 3' ; reverse primer, 5' CACACTAGTCTCGAGGCT-GGAAGAACTACAGAATAC 3') were used to amplify the DNA, allowing directional cloning of the MSPl,, EGF-like modules into pTECH2 that had been previously digested with BamHI and SpeI. The bacterial strains used were E. coli Topp 10 (Stratagene), E. coli TG2 (recA) (Sambrook et al., 1989) , Salmonella typhimurium SL5338 (galE r-m+) (Brown et al., 1987) and the S. typhimurium vaccine strains : SL3261(aroA) (Hoiseth & Stocker, 1981) , BRD726 (AhtrA) (Chatfield et al., 1992) , CSaroD (Miller et al., 1989) and C.5046 (htrA::TnphoA) (Johnson et al., 1991) (referred to in this study as C5htrA). Bacteria were grown aerobically in Luria-Bertani (LB) broth supplemented with 50 pg ampicillin ml-l as required. Salmonella and E. coli Topp 10 cells harbouring pGEX-3X-MSPl,, (Ling et al., 1994) were treated with 1 mM IPTG to induce expression of glutathione S-transferase-MSPl,, (GSTMSPl,,) . Plasmid DNA prepared in E. coli TG2 was first modified by transformation into SL5338 and then electroporated into the different vaccine strains. Preparation of proteins. Glutathione-agarose (Sigma) was used to purify GST-MSPl,, and prepare recombinant MSPl,, (rMSPl,,) as previously described, and referred to as GSTMSPlEGF and MSPlEGF, respectively (Ling et al., 1994) . When necessary, proteins were reduced or reduced and alkylated. Protein (75 pg ml-l) was reduced with 50 mM dithiothreitol. Reduced protein was carboxymethylated by addition of 150 mM sodium iodoacetate, in a solution adjusted to pH 8.5 with NaOH and incubated for 1 h at 37 OC as described in the section on Western blotting assays. Western blotting assays. Expression of the recombinant proteins was assessed by Western blotting. Overnight cultures of the different Salmonella constructs were diluted 1 : 100 and grown to mid-exponential phase (OD,,o approx. 0 6 ) , harvested by centrifugation, and resuspended in one-tenth of the original culture volume of PBS-1 '/o (v/v) Triton X-100. Samples were sonicated on ice with a Soniprep 150, MSE sonicator (Sanyo) set at 10 pm amplitude for 20 s. Aliquots (50 pl) of the sonicated samples were then mixed with an equal volume of twice concentrated loading buffer in the presence of 50 mM dithiothreitol (reduced) (two aliquots) or absence of dithiothreitol (non-reduced) and boiled for 5 min. One of the aliquots containing reduced protein was then carboxymethylated by addition of 150 mM sodium iodoacetate and the solution adjusted to p H 8.5 with NaOH, and incubated for 1 h at 37 "C. At the end of this incubation period, the pH of the sample was readjusted back to pH 7 for electrophoresis. Aliquots of the non-reduced, reduced or reduced and alkylated samples (20 pl) were resolved by SDS-PAGE (12.5% acrylamide) according to the method of Laemmli (1970) . Proteins were transferred to a nitrocellulose membrane (Towbin et al., 1979) and probed with either polyclonal or monoclonal antibodies (mAbs) or immune mouse serum. The polyclonal probes were rabbit anti-TetC serum (Khan et al., 1994a, b) and mouse anti-MSPl,, serum (Ling et al., 1995) . Blots were subsequently probed with horseradish peroxidase (HRP)-conjugated anti-rabbit or antimouse immunoglobulin, respectively (Dako), and developed with 4-chloro-1-naphthol (Sigma). The mAb probes were F5
CACGGATCCGTCGACATGGATGGTATGGATTTAT-
Expression of P. yoelii MSPl,, in Salmonella (1.2 pg ml-') and B10 (3.9 pg ml-l) which recognize conformational epitopes either within the first single EGF-like module (F5) or spanning the two EGF-like modules (B10) of P. yoelii MSPl,, (Spencer Valero et al., 1998) . Blots were subsequently probed with anti-mouse immunoglobulin (Amersham) and developed by enhanced chemiluminescence (Amersham). Animals and immunization protocols. Either inbred female BALB/c or outbred female NIH Swiss mice were used for all immunization studies. Mice were purchased from Harlan Olac (Blackthorn, Bicester, UK) and used when at least 8 weeks old. Groups of 8-22 mice were injected intravenously (i.v.) in a lateral tail vein with 1 x lo6 c.f.u. per mouse of the different recombinant Salmonella, and boosted with the same dose of Salmonella 4 and 9 weeks later. Serum samples were obtained at weeks 3, 5, 7, 11, 13 and 15 following the initial injection, and sera were stored individually at -20 "C. Viable counts in organ homogenates were measured for mice injected with Salmonella 7 and 15 d earlier as described (Khan et al., 1994a, b) . Groups of animals were challenged i.v. with lo3 P. yoelii YM-parasitized erythrocytes 3 d after the final 15 week bleed. The groups were: non-immunized mice, mice immunized with Salmonella strain CSAroD alone, mice immunized with CSaroD(pTECH2) and mice immunized with C5aroD(pTECH2-MSPl1,). Parasitaemia was assessed daily on blood films stained with Giemsa's reagent. Alternatively, female BALB/c mice were immunized intraperitoneally with the GST-MSPl,, fusion protein administered with Freund's adjuvant, and serum obtained, as previously described (Ling et al., 1994) . Anti body responses. Antibody responses were assessed by ELISA or by indirect immunofluorescence. Antibody responses were measured by ELISA as previously described (Khan et at., 1994a, b) . Briefly, each well of a 96-well microtitre plate (Nunc, Gibco-BRL, Life Technologies) was coated overnight at 4 "C with either 0.1 pg recombinant TetC (rTetC) (Boehringer Mannheim) or 0.1 pg recombinant MSPl,, (rMSPl,,) diluted in 0-1 M carbonate buffer, pH 9.6. For the ELISA under reducing conditions, plates were coated with rMSPl,, that had been reduced with 0.05 M dithiothreitol at 37 "C for 1 h before dilution into 0.1 M carbonate buffer, p H 9.6, containing 0.05 M dithiothreitol ; the PBS solutions contained 0.01 M dithiothreitol. Individual serum or pooled serum samples were added at dilutions between 1/100 and 1/1638400 in PBS-1 '/o BSA, and incubated for 1 h at 37 "C.
Serial dilutions of positive control sera were included on all plates. Rabbit anti-mouse total IgG HRP conjugate (Dako) was added diluted 1/1OOO, and incubated for another hour at 37 "C. A solution of o-phenylenediamine (OPD, Sigma), prepared according to the manufacturer's instructions, was added for 15 min at 37 "C. Development of the colour reaction was stopped with 3 M H,SO, and the absorbance was measured at 490 nm. Indirect immunofluorescence assay. Antibody determination by indirect immunofluorescence was carried out as previously described (Holder & Freeman, 1984) . Mouse serum was added to acetone-fixed P. yoelii YM blood stages and bound antibody was detected with FITC-labelled anti-mouse IgG.
RESULTS AND DISCUSSION

Expression of TetC-MSPI,, fusion protein in Salmonella vaccine strains
T h e recombinant plasmid pTECH2-MSPl1, w a s used to transform several attenuated S. typhimurium vaccine strains: SL3261, BRD726, C 5 a r o D a n d CShtrA, a n d the level of expression of t h e fusion protein w a s assessed by Western blotting using polyclonal mouse anti-GSTMSPl,, serum (Fig. l a ) a n d polyclonal rabbit anti-TetC serum (Fig. lb) a s probes. Lysates f r o m each bacterial strain transformed with p T E C H 2 -M S P l l S (lanes 4-7) contained a polypeptide of the approximate size expected for the TetC-MSPl,, fusion (approx. 55-60 k D a ) . Expression of t h e fusion protein appears to be considerably less in SL3261 relative t o the other three vaccine strains, a s evidenced by a fainter 55-60 k D a b a n d (lane 4 compared to lanes 5-7). The lower level of expression in SL3261 (lane 4) is accompanied by increased a m o u n t s of a diffuse, doublet b a n d with a slightly faster mobility t h a n the fusion product, relative to the o t h e r three strains. T h i s m a y represent breakdown products derived f r o m t h e fusion, o r the expression of truncated products. In Fig. l ( a ) , lane 2, the -40 kDa GST-MSPl,, is detected in a lysate of bacteria transformed with pGEX-3X-MSPl1,, a n d in Fig. l(b transformed with pTECH2. Some other polypeptides were detected non-specifically in all lanes.
These results demonstrate that a TetC-MSPl,, fusion protein can be expressed in Salmonella. Since protection with a recombinant P. yoelii MSPl,, is dependent upon correct conformation and disulphide bridge formation (Ling et al., 1994) , we then assessed whether or not the recombinant MSPl,, expressed in Salmonella was capable of forming these conformational epitopes, as judged by reactivity to specific monoclonal antibodies.
Folding and disulphide-bond-dependent conformation of MSPI,, in Salmonella vaccine strains
Folding and formation of disulphide-bond-dependent epitopes in TetC-MSPl,, was evaluated for all four Salmonella vaccine strains by SDS-PAGE and Western blotting. The Western blots of lysates from strains C5aroD and BRD726 are shown in Fig. 2 ; the other two strains gave identical profiles to that of CSaroD. Lysates were prepared from vaccine strains harbouring either pTECH2, pGEX-3X-MSPl1,, or pTECH2-MSPl1,. The blots were probed with the mAbs F5 or B10 [panels (a) and (b) respectively], which recognize different conformational epitopes, and are capable of suppressing parasitaemia when used to passively immunize mice (Spencer Valero et al., 1998) . These mAbs recognize native MSPl in the parasite, and properly folded recombinant MSPl,, in which the appropriate conformational epitopes are formed, but not protein that is Expression of P. yoelii MSPl,, in Salmonella ability of the protein to form intermolecular disulphide bonds in the non-reduced state. The reduced and alkylated rMSPl,, (lane 1, RA) was not recognized by either mAb, as expected, since the protein had been unfolded and prevented from refolding so that the conformational epitopes were permanently destroyed. A similar result was obtained if the protein was not alkylated but kept in the continued presence of reducing agent during Western blotting (data not shown). The rMSPl,, in the sample reduced prior to electrophoresis (lane 1, R) did react with both mAbs, presumably as a result of refolding after electrophoresis, perhaps as a result of oxidation during transfer from gel to nitrocellulose. The reduced rMSPl,, had a greater mobility than the non-reduced protein, in close agreement with the results of others (Burghaus & Holder, 1994 ).
Both the mAbs tested [F5, panel (a) or B10, panel (b)]
recognized the -40 kDa, GST-MSPl,, as indicated by a very heavy band in lanes containing non-reduced bacterial lysates from either C5aroD (i) or BRD726htrA (ii) harbouring the recombinant plasmid pGEX-3X-MSPl,, (lane 3, NR). The additional band at -80 kDa in these non-reduced samples may be a dimer resulting from intermolecular disulphide bond formation. The reduced protein had a lower mobility than the nonreduced protein (lane 3, R). This recognition by antibody and change in mobility are indicative of the production of a properly folded GST-MSPl,, fusion protein in these two attenuated Salmonella strains, as has been previously reported for both the P. yoelii and the P. falciparum GST-MSPl,, fusion proteins expressed in E . coli (Ling et al., 1995; Burghaus & Holder, 1994 ). Further evidence for the disulphide-bonded conformation of MSPl,, in Salmonella and production of a properly folded protein that appears antigenically similar to the natural antigen was obtained by probing blots similar to those in Fig. 2 with hyperimmune serum generated by infection of mice with P. yoelii parasites; this antibody is therefore generated against the natural antigen (Ling et al., 1995) . The recognition pattern of this serum was identical to the mAb recognition patterns with both C5aroD and BRD726htrA lysates (data not shown), suggesting that the hyperimmune serum only reacted with disulphide-dependent conformational epitopes in the purified rMSPl,, and the different Salmonella constructs.
These results together clearly demonstrate that MSPl,, can be expressed in CSaroD as a fusion with either GST or TetC, and contains epitopes that are reduction sensitive. We have shown that conformational epitopes within either the first EGF-like module or spanning the two EGF-like modules of MSPl,, are formed in Salm o nella.
It is particularly noteworthy that the proper folding of MSPl,, appears dependent upon both the Salmonella strain (parental strain and attenuating mutation) and the protein to which the MSPl,, is fused. It is not clear why BRD726 (SL1344 AhtrA), with an attenuating mutation within a heat-shock protein gene (Chatfield et al., 1992; Johnson et al., 1991) , is only able to allow the production of a properly folded MSPl,, when it is fused to GST whereas CSaroD, CShtrA and SL3261 (SL1344 aroA) all allow proper folding of the protein fused to either GST or TetC. Since BRD726 has the same parental background as SL3261 and a mutation in the same gene as CShtrA, it is possible that the combination of parental background and attenuating mutation in BRD726 is responsible. The results here demonstrate the importance of evaluating the antigenicity of vaccine strain panels when expressing different guest antigens in Salmonella.
T o investigate the immunogenicity of MSPl,, delivered by immunization with recombinant Salmonella we next determined the antibody response induced to the protein.
The influence of mouse strain and Salmonella vaccine strain on antibody responses
Groups of eight BALB/c or NIH Swiss mice were immunized with different recombinant Salmonella vaccine strains containing either pTECH2 or pTECH2-MSPl,,. Bacteria were recovered from mouse liver and spleen 7 or 15 d after i.v. immunization and grown on media with and without ampicillin to determine how many had retained the plasmid. More than 9.5% of - Table I . Comparison of antibody responses against rMSP1 ,9 and rTetC as detected by ELISA analysis of sera from NIH Swiss and BALB/c mice immunized i.v. with various S.
typhimurium strains
Mice were immunized with 1 x lo6 c.f.u. per mouse of the recombinant Salmonella and boosted by repeat immunization with the same dose on weeks 4 and 9. Results are expressed as the geometric mean (GM) of A,,, values for week 13 sera, diluted 1/100, from groups of four or five mice. Standard deviations (SD) are given. Antibody responses were measured against rMSPl,, (a) or rTetC (b). Pooled sera from five non-immunized mice were included in each experiment ; they had A,,, values of <0.06. ELISA measurements were made in duplicate. bacteria in all cases had retained the plasmid. Table 1 shows the geometric means and standard deviations of the antibody responses against rMSPl,, (a) and rTetC (b) in groups of BALB/c or NIH Swiss mice. There was considerable variation in response against rMSPl,, within the individual groups of both inbred and outbred mice, but the reason for this is unclear. The Swiss mice produced an overall greater response against rMSPl,, than the BALB/c mice but the difference was not significant. Swiss mice immunized with CSaroD carrying pTECH2-MSPl1, elicited the greatest response, achieving high antibody responses in 4/5 mice. These data indicate that attenuated recombinant Salmonella induce antibodies against rMSPl,,.
Both strains of mice developed high anti-TetC responses when immunized with recombinant Salmonella strains carrying either pTECH2 alone (column 2) or carrying pTECH2-MSPl1, (columns 3-6), with slightly higher responses observed overall with the Swiss mice. The level of antibody response to TetC was apparently higher and less variable than that to MSPl,,, suggesting that the TetC part of the molecule was immunodominant.
It was important next to establish that the antibodies against recombinant MSPl,, react with the native protein in the parasite and recognize conformational epitopes.
Antibody responses induced by C5aroD(pTECH2-MSPI,,) compared to those induced by purified GST-MSPI,,
Antiserum from Swiss mice immunized with C5aroD (pTECH2-MSPl1,) was evaluated for its ability to recognize MSPl expressed by P. yoelii parasites. Fig. 3 shows the reactivity of the antiTetC-MSPl,, serum with acetone-fixed P. yoelii-infected erythrocytes as determined by immunofluorescence. Negative control serum from non-immunized mice or mice immunized with a Salmonella vaccine strain containing pTECH2 did not exhibit any specific reactivity (data not shown), while the positive serum gave a 'bunch of grapes like' fluorescence pattern corresponding to detection of MSPl on the surface of budding merozoites in mature schizonts.
We then sought to establish the proportion of antiMSPl,, antibody from mice immunized with C5aroD (pTECH2-MSPl1,) that is directed against conformational epitopes, using an ELISA. Pooled serum from four mice immunized with C5aroD(pTECH2-MSPll9) contained a very high level of antibody reacting with non- reduced rMSPl,, (A,,, reading off the scale at 1/100 serum dilution) but a much lower level of antibody against the reduced, unfolded protein (A490 0.53), representing less than 20% of the total MSP1-specific antibody. Serum from mice immunized with GSTMSPl,, in the presence of Freund's adjuvant, and known to be protected against challenge infection with P. yoelii (Ling et al., 1994 ), had a very high level of antibody reacting with non-reduced rMSPl,, when measured at a l/5000 dilution. These antibodies did not react with reduced MSPl,,, demonstrating that this method of immunization induces antibodies directed against conformational epitopes within the protein which is similar to the situation for protective antibodies following immunization with a recombinant GST-MSPl,, in a strong adjuvant.
The magnitude of the antibody response against MSPl,, is also a critical factor in determining the level of protection against challenge infection with P. yoelii parasites (Ling et al., 1994) . Therefore, the antibody titres of 12 of a group of 22 mice immunized with CSaroD(pTECH2-MSPl1,) were determined by ELISA against rMSPl,, and rTetC. These 12 mice were a representative sample from the group. Fig. 4 shows the titration curves of the individual sera measured against rMSPl,, (a) and rTetC (b). Each of the mice immunized with the C5aroD(pTECH2-MSPl1,) had a much lower level of antibody to rMSPl,, than mice immunized with GST-MSPl,, administered with Freund's adjuvant, which had a titre at least twofold greater (Fig. 4a , dotted line). By indirect immunofluorescence an even greater difference was observed between serum from mice immunized with the recombinant Salmonella (titres 1/25-1/800) and the serum from the mice immunized with GST-MSPl,, (titre approximately 1/10000) and protected against challenge infection.
ELISA analysis of the IgG subclass distribution of the anti-MSPl,, antibody response in mice immunized i.v. with ) showed that the mice developed specific IgGl and IgG2b together with IgG2a, a similar subclass distribution to that observed with antiserum from mice immunized with the GST-MSPl,, (data not shown).
Despite the quantitative differences in the antibody levels in mice immunized by Salmonella infection and those immunized with purified recombinant protein administered with adjuvant, we determined whether or IP: 54.70.40.11
On: Sun, 06 Jan 2019 06:44:25 E. A. SOMNER a n d OTHERS not the response induced by Salmonella immunization was sufficient to protect against parasite challenge.
Parasite challenge
Groups of Swiss mice were challenged by inoculation of lo3 P. yoelii-infected erythrocytes and monitored daily. Immunization with C5aroD(pTECH2-MSPl1,) slightly delayed (by 1 d) the onset of patent parasitaemia and prolonged the survival of 4/12 mice compared to control groups (from 10 to 11 d), but did not protect the mice (data not shown). There was no correlation between antibody titre and onset of parasitaemia or survival time.
Overall, these data suggest that the reason for the lack of protection observed in the challenge study is likely to be based on the magnitude of the antibody response. The amount of antigen delivered to the mouse immune system by infection with recombinant Salmonella is unknown but may be less than that delivered by immunization with purified recombinant GST-MSPl,, and this may be responsible for the lower antibody response. The correctly folded TetC-MSPl,, fusion protein expressed in CSaroD appears to induce antibody that is primarily directed against conformational epitopes within the recombinant protein, suggesting that the fine specificity of the immune response may not be responsible for the lack of protection we observed. However, it is possible that the humoral response is directed to irrelevant epitopes, which are conformational but are not important in protection. Previous workers have demonstrated that the route of inoculation, and the adjuvant employed, have a profound effect on the fine specificity of the antibodies elicited against P. yoelii (Daly & Long, 1996) . Furthermore, others have shown that mAbs, specific for P. falciparum
MSPl and able to competitively inhibit the binding of each other have dramatically differing abilities to inhibit parasite growth in vitro. Some of these mAbs effectively inhibit invasion of red blood cells whilst others that can block this inhibition do not prevent invasion (Blackman et al., 1994) . It is possible that the carboxy-terminus of P. yoelii MSPl also induces the production of antibodies that exhibit similar properties, although this has not been demonstrated.
In summary, the data show that antigenic MSPl,, can be expressed in Salmonella in a form that reacts with protective mAbs. In addition, infection with an attenuated strain expressing TetC-MSPl,, induces antibodies that recognize the native parasite protein and are directed against conformational epitopes shown to be important targets of a protective immune response. However, the magnitude of the antibody response was lower than that achieved by immunization with a recombinant protein and adjuvant. Therefore, the balance of evidence suggests that the magnitude of the antibody response is the most likely reason for the lack of protection against challenge infection (Daly & Long, 1995; Ling et al., 1994) . Further studies are now required to improve the immunogenicity of this antigen in the attenuated bacterial delivery system.
